P-043 - LONGITUDINAL PHARMACODYNAMIC (PD) MODELS TO INVESTIGATE EFFICACY AND OCULAR SAFETY FOLLOWING BELANTAMAB MAFODOTIN (BELAMAF) ADMINISTRATION IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM).
J. Collins1, M. van Noort2, C. Rathi3, T. Post4, H. Struemper1, R. Jewell1, G. Ferron-Brady3; 1GlaxoSmithKline, Research Triangle Park, NC, USA, 2Leiden Experts on Advanced Pharmacokinetics and Pharmacodynamics, Leiden, The Netherlands, 3GlaxoSmithKline, Collegeville, PA, USA, 4Leiden Experts on Advanced Pharmacokinetics and Pharmacodynamics, Leiden, Netherlands.